Copy to clipboard 
Surgify Medical, developer of Surgify Halo technology, has successfully raised €7 million (USD $7.9 million) in Series A funding.
Building on a successful Nordic market launch, the company will expand its operations in the EU and the United States, where key hospitals have already started adopting Surgify’s technology.
Surgify Halo cuts bone while providing protective capabilities against incidental injuries to soft tissues such as central nervous system structures, blood vessels and nerves. The technology provides effective bone resection in combination with a soft tissue protection feature for enhanced safety and precision in surgical procedures. Surgify Halo is MDR- and FDA-cleared.
Conventional surgical drills spin tens of thousands of times per minute and can be dangerous if they come into contact with critical soft tissue. At worst, such soft tissue damage can result in severe injury to the patient. Soft tissue injuries are considered a highly relevant surgical complication in many types of head, neck and spine procedures involving bone resection.
The funding round was led by ZEISS Ventures, the corporate venture arm of the Carl Zeiss Group, with participation from the European Innovation Council Fund (EIC Fund). Surgify’s existing investors, including Lednil and Cascara Ventures, also participated in the financing.
Source: Surgify Medical
“ZEISS brings unparalleled experience in surgical technology and a global network, while the EIC’s continued support and earlier grant financing underscore the European innovation ecosystem’s confidence in our solution,” said Visa Sippola, Co-founder and CEO of Surgify Medical. “With this funding and regulatory approvals in both the EU and the U.S., we are well-positioned to bring our unique technology to more surgeons and patients internationally.”
“Surgify’s technology is a major breakthrough in today’s evolving healthcare landscape. With over a thousand patient procedures, Surgify HaloTM has already left a significant footprint in the field. The company aims to protect patients, save costs, and has already achieved groundbreaking developments in robotic surgery applications,” stated Alan Raffensperger, Chairman of Surgify Medical.
“We are excited to partner with Surgify in their mission to establish a new benchmark for surgical safety. Surgify’s Halo™ burrs offer exceptional control at cutting rates comparable to traditional burrs, while simultaneously safeguarding delicate soft tissues. This makes the switch to Halo™ burrs an obvious choice for surgeons,” explains Dr. Boris Hofmann, Head of ZEISS Ventures. “We are eager to support the team as they expand their solution on a global scale.”
“The EIC Fund is proud to support Surgify’s groundbreaking approach to safer and more precise bone surgery. Their technology holds strong potential to significantly improve surgical outcomes and patient safety globally,” says Svetoslava Georgieva, Chair of the EIC Fund Board.
Surgify Medical, developer of Surgify Halo technology, has successfully raised €7 million (USD $7.9 million) in Series A funding.
Building on a successful Nordic market launch, the company will expand its operations in the EU and the United States, where key hospitals have already started adopting Surgify's technology.
Surgify Halo cuts...
Surgify Medical, developer of Surgify Halo technology, has successfully raised €7 million (USD $7.9 million) in Series A funding.
Building on a successful Nordic market launch, the company will expand its operations in the EU and the United States, where key hospitals have already started adopting Surgify’s technology.
Surgify Halo cuts bone while providing protective capabilities against incidental injuries to soft tissues such as central nervous system structures, blood vessels and nerves. The technology provides effective bone resection in combination with a soft tissue protection feature for enhanced safety and precision in surgical procedures. Surgify Halo is MDR- and FDA-cleared.
Conventional surgical drills spin tens of thousands of times per minute and can be dangerous if they come into contact with critical soft tissue. At worst, such soft tissue damage can result in severe injury to the patient. Soft tissue injuries are considered a highly relevant surgical complication in many types of head, neck and spine procedures involving bone resection.
The funding round was led by ZEISS Ventures, the corporate venture arm of the Carl Zeiss Group, with participation from the European Innovation Council Fund (EIC Fund). Surgify’s existing investors, including Lednil and Cascara Ventures, also participated in the financing.
Source: Surgify Medical
“ZEISS brings unparalleled experience in surgical technology and a global network, while the EIC’s continued support and earlier grant financing underscore the European innovation ecosystem’s confidence in our solution,” said Visa Sippola, Co-founder and CEO of Surgify Medical. “With this funding and regulatory approvals in both the EU and the U.S., we are well-positioned to bring our unique technology to more surgeons and patients internationally.”
“Surgify’s technology is a major breakthrough in today’s evolving healthcare landscape. With over a thousand patient procedures, Surgify HaloTM has already left a significant footprint in the field. The company aims to protect patients, save costs, and has already achieved groundbreaking developments in robotic surgery applications,” stated Alan Raffensperger, Chairman of Surgify Medical.
“We are excited to partner with Surgify in their mission to establish a new benchmark for surgical safety. Surgify’s Halo™ burrs offer exceptional control at cutting rates comparable to traditional burrs, while simultaneously safeguarding delicate soft tissues. This makes the switch to Halo™ burrs an obvious choice for surgeons,” explains Dr. Boris Hofmann, Head of ZEISS Ventures. “We are eager to support the team as they expand their solution on a global scale.”
“The EIC Fund is proud to support Surgify’s groundbreaking approach to safer and more precise bone surgery. Their technology holds strong potential to significantly improve surgical outcomes and patient safety globally,” says Svetoslava Georgieva, Chair of the EIC Fund Board.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
